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and the sensitive impairment of quality of life signiﬁcantly con-
tribute to the high socioeconomic burden of AD.
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OBJECTIVES: To assess the impacts of Elidel® (pimecrolimus)
cream 1% usage, in routine Belgian clinical practice in patients
with mild to moderate atopic dermatitis, in terms of: pime-
crolimus drug consumption; use of topical corticosteroids;
quality of life; and safety. METHODS: An open-label, single
arm, observational, multicenter study with one year follow-up
to cover the seasonality of atopic dermatitis. Yearly pime-
crolimus drug consumption was estimated based on the number
and quantity of delivered prescriptions and on the number of
unused or partially used tubes left at the end of the study. Topical
corticosteroid use was assessed by a steroid usage questionnaire
and the delivered topical corticosteroid prescriptions. Quality of
life was gauged using validated disease speciﬁc instruments, i.e.
the Parents’Index Quality of Life-Atopic Dermatitis (PIQoL-AD)
or the Quality of Life Index-Atopic Dermatitis (QoLIAD),
depending on patient’s age. All adverse events were recorded.
RESULTS: A total of 416 patients were enrolled from 49 study
centers geographically spread over Belgium. For patients who
completed this 12 months study, the mean (SD) amount of pre-
scribed pimecrolimus cream 1% per patient was 120.8 (117.0)
gram per year, with an estimated consumption of 104.4 (117.6)
gram per year. Topical corticosteroids were used before the study
in 81.7% of the population. At the end of study 83.3% of them
stated that they were using less topical corticosteroids when
pimecrolimus is part of their treatment regimen. Mean (SD)
improvements versus baseline in PIQoL-AD and QoLIAD scores
were 34.5% (84.3%) and 31.2% (70.8%), respectively. Median
(IQR) improvements were 50.0% (12.5%–85.7%) and 46.4%
(0.0%–85.0%), respectively. Pimecrolimus also showed good
tolerability proﬁle. CONCLUSIONS: This observational study
showed favorable pimecrolimus proﬁle in routine practice
reﬂected by relatively small amount of drug used, corticosteroid
sparing effect, improvement in quality of life, and good 
tolerability.
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Generic Quality of Life (QoL) instruments are useful to compare
different populations. However these instruments could be crit-
icized for having some drawbacks, and disease-speciﬁc instru-
ments could be preferred to measure those aspects of wellbeing
inﬂuenced by a speciﬁc disease and to effectively measure health
changes over the time. OBJECTIVE: We tested convergent valid-
ity and sensitivity to change over time of a generic and disease-
speciﬁc pediatric questionnaires to evaluate wellbeing in children
with Atopic Dermatitis (AD), a very frequent, chronic and dis-
abling disease. METHODS: Data from the Costi-&-Outcomes-
in-Dermatite-Atopica (CODA) naturalistic, prospective Cost-Of-
Illness study, involving moderate and severe AD patients, were
used. Patients aged 5–16 y.o. and/or their caregivers completed
twice (at ﬂare-up and after 2 months) the KINDL (children-
reported version: KINDL-C, parent-reported version: KINDL-P;
scores = 0–100, higher score = higher QoL) and CDLQI (Chil-
dren’s-Dermatology-Life-Quality-Index, with scores = 0–30,
higher score = lower QoL). Patients’ clinical status was evalu-
ated with the SCORAD index (SCORing-Atopic-Dermatitis,
possible score = 0–100, higher score = higher severity). We tested
convergent validity by investigating correlations between QoL
instruments; sensitivity to change over time was tested with
paired students’ t tests, Standardized Response Mean (SRM),
Effect Size (EF). RESULTS: Pediatric patients were 66, 43.9%
male, median age = 8.8 y.o., median SCORAD at enrolment =
41.5 (3.0–85.0). CDLQI signiﬁcantly correlated with KINDL-P
(Spearman’s r = −0.44 p = 0.001) and KINDL-C (r = −0.36 p =
0.008), KINDL-P sensitively correlated with KINDL-C (r = 0.67
p < 0.0001). At follow-up clinical severity signiﬁcantly decreased
(Student’s paired t test, p < 0.0001). Patients reported signiﬁcant
lower scores of CDLQI (Student’s paired t test, p < 0.05), while
no statistical change was found with KINDL-P and KINDL-C.
SRM and ES were moderate for CDLQI (SRM = 0.44, ES = 0.41)
and low for KINDL-C (SRM = 0.26, ES = 0.26) and KINDL-P
(SRM = 0.12, ES = 0.11). CONCLUSION: KINDL signiﬁcantly
correlated with CDLQI, anyway sensitivity to change results
were moderate to low. Understanding these properties in QoL
questionnaires is necessary to allow their appropriate use and
interpretation of QoL data.
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Generic instruments such as EQ-5D are useful to compare
quality of life (QoL) of different populations and to include QoL
information in health-economic research. However these instru-
ments could be criticized for having some drawbacks, and
disease-speciﬁc instruments could be more capable to measure
those aspects of wellbeing inﬂuenced by a speciﬁc disease and
could be more sensitive to measure health changes over the time.
OBJECTIVE: We tested convergent validity and sensitivity to
change over time of EQ-5D and the Dermatology-Life-Quality-
Index (DLQI, possible scores = 0–30, higher score = lower QoL)
in Atopic Dermatitis (AD), a very frequent, chronic, sensitively
disabling disease. METHODS: Data from the Costi-&-Out-
comes-in-Dermatite-Atopica (CODA) naturalistic, prospective,
Cost-Of-Illness study, involving moderate and severe AD
patients, were used. Socio-demographic, clinical severity (with
SCORAD, SCORing-Atopic-Dermatitis index, possible score =
0–100, higher score = higher severity), economic and QoL data
were collected. Patients from 16 y.o. self-completed twice (at
ﬂare-up and after 2 months) EQ-5D and DLQI. We tested cor-
relation of EQ-5D indexes with DLQI and sensitivity to change
over time of these indexes with paired Students’ t tests, Stan-
dardized Response Mean (SRM), Effect Size (EF). RESULTS:
Patients were 98, 48% male, median age = 30.5 y.o. (18–77). At
enrolment median SCORAD = 53.0 (18.4–90.0), median EQ-
VAS = 65.0 (0.0–95.0), median utility score from EQ-proﬁle =
